FactSet Surveyed Analyst Ratings and Target Price for Adaptive Biotechnologies

Summary

According to a FactSet survey of analysts, the average rating for Adaptive Biotechnologies is ‘Buy’, with an average price target of $11.86.Trading View

Impact Analysis

This event is classified at the Company Level as it specifically pertains to Adaptive Biotechnologies. The FactSet survey results indicate positive analyst sentiment, which could enhance investor confidence and potentially lead to an increase in stock price. The ‘Buy’ rating suggests that analysts believe the company’s future prospects are strong, which might attract new investors or encourage current investors to hold their positions. The average price target of $11.86 provides a benchmark for investors, offering insights into potential upside. However, investors should consider this information in the context of broader market conditions and any recent company developments not covered in the summary.Trading View